Clear Cell Renal Cell Carcinoma Clinical Trials

23 recruiting

Clear Cell Renal Cell Carcinoma Trials at a Glance

41 actively recruiting trials for clear cell renal cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 20 trials, with the heaviest enrollment activity in Duarte, Houston, and New York. Lead sponsors running clear cell renal cell carcinoma studies include Arcus Biosciences, Inc., City of Hope Medical Center, and Fudan University.

Browse clear cell renal cell carcinoma trials by phase

Treatments under study

About Clear Cell Renal Cell Carcinoma Clinical Trials

Looking for clinical trials for Clear Cell Renal Cell Carcinoma? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Clear Cell Renal Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Clear Cell Renal Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 41 trials

Recruiting
Phase 1

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Solid TumorsClear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.362 enrolled25 locationsNCT05536141
Recruiting
Phase 3

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.720 enrolled44 locationsNCT07011719
Recruiting
Phase 2

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Clear Cell Renal Cell Carcinoma+2 more
City of Hope Medical Center62 enrolled2 locationsNCT07037004
Recruiting
Phase 2

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Metastatic Clear Cell Renal Cell Carcinoma+1 more
Vanderbilt-Ingram Cancer Center54 enrolled6 locationsNCT05361720
Recruiting
Phase 1Phase 2

Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma

Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Beijing Biotech36 enrolled1 locationNCT07551349
Recruiting
Phase 1Phase 2

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Metastatic Renal Cell CarcinomaCarcinoma, Renal CellAdvanced Renal Cell Carcinoma+8 more
Pfizer224 enrolled49 locationsNCT07227415
Recruiting
Phase 2

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Endometrial CancerLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+10 more
Rahul Aggarwal89 enrolled3 locationsNCT03682289
Recruiting
Phase 1Phase 2

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Advanced CancerClear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center100 enrolled1 locationNCT05663710
Recruiting
Phase 3

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell CarcinomaStage II Renal Pelvis Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,040 enrolled409 locationsNCT06661720
Recruiting
Phase 2

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Metastatic Renal Cell CarcinomaAdvanced Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Karie Runcie70 enrolled2 locationsNCT06863311
Recruiting
Phase 2

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Metastatic Renal Cell CarcinomaRenal Cell CarcinomaKidney Cancer+3 more
Stephanie Berg25 enrolled2 locationsNCT07123090
Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Metastatic Cervical CarcinomaMetastatic Endometrial CarcinomaMetastatic Lung Non-Small Cell Carcinoma+24 more
Mayo Clinic324 enrolled3 locationsNCT06349642
Recruiting
Phase 2

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NeoplasmsClear Cell Renal Cell CarcinomaMalignant Neoplasms+1 more
Yonsei University78 enrolled1 locationNCT07469683
Recruiting
Phase 1

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Renal Cell CarcinomaClear Cell Renal Cell CarcinomaKidney Cancers+6 more
Neomorph, Inc30 enrolled7 locationsNCT07300241
Recruiting
Phase 1

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma
Xencor, Inc.307 enrolled23 locationsNCT05433142
Recruiting
Phase 2

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma
University of Oklahoma72 enrolled1 locationNCT07223541
Recruiting
Phase 1

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Metastatic Clear Cell Renal Cell Carcinoma+3 more
City of Hope Medical Center33 enrolled2 locationsNCT07128680
Recruiting
Phase 2

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Neoadjuvant TherapyClear Cell Renal Cell CarcinomaIparomlimab and Tuvonralimab
Sun Yat-sen University25 enrolled1 locationNCT07389629
Recruiting
Phase 2

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center10 enrolled1 locationNCT07187778
Recruiting
Phase 1

[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma

Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Orhan Kemal Oz35 enrolled1 locationNCT04989959